Ruxolitinib+Calcineurin inhibitor+Methotrexate
RCMvsCM
Unknown small_molecule completed
Quick answer
Ruxolitinib+Calcineurin inhibitor+Methotrexate for Graft Versus Host Disease is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Graft Versus Host Disease
- Phase
- Unknown
- Modality
- small_molecule
- Status
- completed